⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 10, 2024Frontiers in OncologyOpen Access

Transplant-associated thrombotic microangiopathy in pediatrics: incidence, risk factors, therapeutic options, and outcome based on data from a single center

Kinan Kafa Jessica I. Hoell

View Full Paper

Ask AI

Bookmark

Share

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a critical complication of hematopoietic stem cell transplantation. Awareness about TA-TMA has increased in recent years, resulting in the implementation of TA-TMA screening in most centers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kafa et al. (2024) studied this question.

synapsesocial.com/papers/68e60ce0b6db6435875a0039 https://doi.org/10.3389/fonc.2024.1399696

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplantCohort Study · 2020 · 96 citations
2Characteristics and outcomes of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy: A retrospective single-center analysis2025
3Hematopoietic stem cell transplant–associated thrombotic microangiopathy: review of pharmacologic treatment optionsreview · 2014 · 59 citations
4Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk NeuroblastomaReview · 2019 · 19 citations
5Risk factors for transplant-associated thrombotic microangiopathy in pediatric patients undergoing haploidentical hematopoietic stem cell transplantation2025